April 18, 2012

Metabolix Opens First European Office

Cologne, Germany location enables leading bioscience company to directly access the European market for biopolymers and renewable chemicals

CAMBRIDGE, Mass. & COLOGNE, Germany--(BUSINESS WIRE)-- Metabolix, Inc. (NASDAQ: MBLX), a bioscience company focused on developing clean, sustainable solutions for plastics, chemicals and energy, today announced the opening of its new office in Cologne, Germany. Located in the BioCampus Cologne life science park, the space will enable the Company to directly access the European market for biopolymers and will serve as a coordination point for its regional initiatives in renewable chemicals. The new office marks the first expansion for Metabolix outside of the United States and will coordinate business development, customer service and technical support to business partners and biopolymer customers based in Europe.

"Countries in the European Union are keenly focused on sustainability initiatives and are taking decisive steps to drive the adoption of 'green' alternatives to conventional plastics and chemicals," said Richard P. Eno, president and CEO of Metabolix. "Opening a German office in an area of thriving life science innovation will put Metabolix in a central location to serve the needs of our customers and business partners."

Metabolix's new office opened its doors on April 16. For more than 100 years, plant-based pharmaceuticals have been produced at the site of BioCampus Cologne which was established in 2002 and is currently one of the largest biotechnology parks in Germany. The park is home to approximately 20 life science companies, including Bayer HealthCare, Sanofi-Aventis and Direvo.

According to the Freedonia Group1, global demand for bioplastics is expected to more than triple through 2015, with Western Europe remaining the largest consumer of bioplastic materials. With more than 700 issued and pending patents, Metabolix has led the industry in the development of a family of biopolymers called PHAs (polyhydroxyalkanoates). Metabolix's technology platform has led to the development of a line of biopolymer resins marketed under the Mirel™ and Mvera™ brands, as well as the development of biobased industrial chemicals as "drop in" replacements for petroleum-based products.

The Mirel and Mvera brands share the physical properties of petroleum-based resins for performance and durability and can be processed on existing equipment with similar productivity and post-processing techniques. The difference is that Metabolix biopolymers display unique biodegradability properties. Mirel is certified to biodegrade in soil and water environments, as well as home composting and industrial composting facilities. Mvera is a certified compostable film grade biopolymer intended for industrial composting. Metabolix biopolymers represent a distinctive solution as a high-performance bioplastic alternative. Metabolix's customers have demonstrated use of PHA biopolymers in agriculture/horticulture, compost and organic waste diversion, marine/aquatic, sustainable packaging and consumer goods applications.

In recent months, Metabolix has produced biobased gamma-Butyrolactone ("GBL," a C4 chemical) at semi-works scale (60,000L) and has produced biobased acrylic acid (a C3 chemical) at lab scale. The Company is actively moving these processes towards commercial scale targets. According to industry sources, the current combined global market for conventional four-carbon ("C4") and three-carbon ("C3") industrial chemicals is estimated at more than $10 billion annually. C4 chemicals are used in applications ranging from high-performance engineering plastics to spandex. C3 chemicals have applications in paints, coatings, diapers and adhesives.

About Metabolix

Founded in 1992, Metabolix, Inc. is an innovation-driven bioscience company focused on providing sustainable solutions for the world's needs for plastics, chemicals and energy. The Company is taking a systems approach, from gene to end product, integrating sophisticated biotechnology with advanced industrial practice. Metabolix is developing biosourced industrial chemicals and plastics, as well as a proprietary platform technology for co-producing plastics, chemicals and energy from crops.

For more information, please visit www.metabolix.com. (MBLX-G)

Safe Harbor for Forward-Looking Statements

This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements in this release do not constitute guarantees of future performance. Investors are cautioned that statements in this press release which are not strictly historical statements, including, without limitation, statements regarding the demand for biopolymers and biobased chemicals, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated and are detailed in Metabolix's filings with the Securities and Exchange Commission, including its 10-K for the year ended December 31, 2011, which was filed on March 12, 2012. Metabolix assumes no obligation to update any forward-looking information contained in this press release or with respect to the announcements described herein.

1 The Freedonia Group, "World Bioplastics to 2015," http://www.freedoniagroup.com/DocumentDetails.aspx?DocumentId=563324

Media:
Metabolix
Lynne Brum, 617-682-4693
LBrum@metabolix.com
or
Schwartz MSL Boston
Keith Giannini or Kirsten Swenson, 781-684-0770
metabolix@schwartzmsl.com
or
Investors:
ICR
James Palczynski, 203-682-8229
james.palczynski@icrinc.com

Source: Metabolix, Inc.

News Provided by Acquire Media


Close window | Back to top

Copyright 2017 Yield10 Bioscience, Inc.